174 related articles for article (PubMed ID: 20979937)
1. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis.
Milovanovic JR; Jankovic SM
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):428-36. PubMed ID: 21726493
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
5. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
[TBL] [Abstract][Full Text] [Related]
6. Valproate population pharmacokinetics in children.
Serrano BB; García Sánchez MJ; Otero MJ; Buelga DS; Serrano J; Domínguez-Gil A
J Clin Pharm Ther; 1999 Feb; 24(1):73-80. PubMed ID: 10319910
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of valproate in Mexican children with epilepsy.
Correa T; Rodríguez I; Romano S
Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
[TBL] [Abstract][Full Text] [Related]
8. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
Eur J Clin Pharmacol; 1998 Mar; 54(1):69-74. PubMed ID: 9591934
[TBL] [Abstract][Full Text] [Related]
9. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
10. Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.
Bondareva IB; Jelliffe RW; Andreeva OV; Bondareva KI
J Clin Pharm Ther; 2011 Oct; 36(5):625-36. PubMed ID: 21062333
[TBL] [Abstract][Full Text] [Related]
11. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of lamotrigine in patients with epilepsy.
Milovanovic JR; Jankovic SM
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):752-60. PubMed ID: 19954714
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of valproate in Chinese children with epilepsy.
Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetic modelling of valproate in epileptic patients].
Jakovljević MB; Janković SM; Todorović N; Milovanović JR; Janković S
Med Pregl; 2010; 63(5-6):349-55. PubMed ID: 21186545
[TBL] [Abstract][Full Text] [Related]
16. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.
Blanco-Serrano B; Otero MJ; Santos-Buelga D; García-Sánchez MJ; Serrano J; Domínguez-Gil A
Biopharm Drug Dispos; 1999 Jul; 20(5):233-40. PubMed ID: 10594867
[TBL] [Abstract][Full Text] [Related]
17. Influence of carbamazepine-10,11-epoxide on the serum level of valproic acid in epileptic patients on combined treatment with carbamazepine and valproic acid.
Minkova GD; Getova DP
Folia Med (Plovdiv); 2000; 42(3):16-9. PubMed ID: 11347330
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.
EL Desoky ES; Fuseau E; EL Din Amry S; Cosson V
Eur J Clin Pharmacol; 2004 Jan; 59(11):783-90. PubMed ID: 14673555
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model.
Gu X; Zhu M; Sheng C; Yu S; Peng Q; Ma M; Hu Y; Li Z; Jiao Z; Zhou B
Eur J Clin Pharmacol; 2021 Jul; 77(7):999-1009. PubMed ID: 33423079
[TBL] [Abstract][Full Text] [Related]
20. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
Vučićević K; Jovanović M; Golubović B; Kovačević SV; Miljković B; Martinović Ž; Prostran M
Eur J Clin Pharmacol; 2015 Feb; 71(2):183-90. PubMed ID: 25380628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]